URGO is a French healthcare and consumer-health brand established in 1958 in Dijon, France, by pharmacist Jean Le Lous. Initially created to provide modern, ready-to-use dressings to consumers and pharmacies, URGO has expanded into a broad brand specializing in wound care, skin repair, first aid, and everyday health issues. It serves as the flagship consumer brand for the family-owned URGO Group, an international French healthcare conglomerate. 1

The figures above refer to the URGO Group rather than the URGO consumer brand alone. The Group reported €930 million in revenue in 2025, with approximately 4,000 employees, operations in 20 countries, and 60% of revenue generated internationally. 1

Foundation: 1958

URGO’s origins trace back to Dijon, Burgundy, where Jean Le Lous worked as a pharmacist and head of Laboratoires Fournier. Having experienced dressing shortages during wartime, he aimed to establish a French business capable of making dressings more accessible to ordinary consumers and pharmacies.

He launched the URGO brand in 1958, initially focusing on ready-to-use dressings. A distinguishing early feature was the use of an aerated backing, designed to enhance comfort and practicality. 2

The brand became strongly associated in France with the slogan:

« Y’a de l’URGO dans l’air, y’a de l’air dans URGO »

Introduced in 1979, this advertising slogan played a significant role in establishing URGO’s popular identity. 3

Development under Hervé Le Lous

The second generation of the Le Lous family contributed significantly to the development of the wider business. Hervé Le Lous, Jean’s son, began his entrepreneurial activities in 1987 and subsequently developed the foundation of the modern URGO Group.

The group’s strategy expanded beyond traditional dressings into broader consumer healthcare through acquisitions such as Mercurochrome in 1996 and Marie Rose and Super Diet in 1997, followed later by brands including Alvityl, Herbesan, and OM3. 4

It is important to distinguish between entities: URGO is a brand, while URGO Group is the larger corporate entity containing URGO and numerous other healthcare brands.

URGO’s identity has historically been built around wound care. During the 2000s, the group substantially increased investment in research and development, shifting from conventional adhesive dressings toward products designed to actively support the wound-healing process.

A major milestone was the development of lipido-colloid technology, which became the basis for advanced medical dressings and led to the creation of URGO Medical, the division dedicated to professional wound care. 5

URGO Medical focuses particularly on complex wounds, including:

• Chronic wounds
• Diabetic foot wounds
• Venous leg ulcers
• Pressure ulcers
• Burns
• Postoperative wounds

This division operates primarily in the professional healthcare market, whereas the URGO consumer brand maintains high visibility in pharmacies and everyday first-aid products.

Today, URGO’s consumer products extend considerably beyond ordinary plasters. The brand’s portfolio includes solutions for:

First Aid and Wounds

Products designed to protect and manage everyday cuts, scratches, superficial wounds, and other minor injuries.

Blisters and Feet

URGO has a substantial presence in blister protection and foot care, offering products intended to protect irritated or damaged areas from friction.

Burns and Skin Injuries

The brand offers products for managing certain superficial skin injuries and supporting skin repair.

Cracked and Damaged Skin

URGO develops products for problems such as cracked hands, damaged skin, and fissures.

Mouth and Lips

The portfolio includes products for everyday issues such as canker sores and cold sores.

Nails

URGO offers specialized solutions for damaged nails and nail-related problems.

Acne and Skin Imperfections

Its more recent portfolio includes products aimed at acne-prone skin and imperfections, demonstrating the brand’s expansion beyond conventional first aid. 6

In essence, URGO has progressively repositioned itself from being simply a “plaster brand” into a broader everyday skin and minor-health-care brand.

Technology is a central element of URGO’s brand positioning.

Filmogel®

Filmogel® is one of URGO’s best-known proprietary technologies. Developed in French R&D laboratories, it utilizes a liquid formulation that forms a flexible protective film when applied to the skin. URGO describes it as creating a “second-skin” effect.

The technology was first introduced commercially in 2002, initially for cracked hands. It subsequently became the basis for products addressing several localized skin problems, including canker sores, cold sores, superficial wounds, insect bites, and damaged nails.

Unlike conventional adhesive plasters, the concept involves:
Liquid formulation → application → formation of a protective film → protection of the affected area.

This technology helped URGO differentiate itself in pharmacy shelves where conventional adhesive dressings were already highly commoditized.

Lipido-Colloid Technology

URGO’s lipido-colloid (TLC) technology is particularly important in professional wound care. Originating around 2000, it became associated with advanced dressings designed to create a favorable environment for wound healing, contributing to the development of URGO Medical’s professional wound-care business.

Other Technologies

URGO’s current technology portfolio also includes:

• Hydrocolloid
• Filmomousse®
• Filmocrème®
• Medical honey
• TENS
• Microneedling / micro-needle technologies
• Syndet cleansing technology

These technologies reflect the brand’s broader move toward skin health rather than traditional wound covering alone.

The distinctions between these names are often confusing:

URGO

The consumer-facing brand best known for dressings, first aid, skin care, blister care, and other everyday healthcare products.

Laboratoires URGO / URGO Healthcare

The business responsible for developing and marketing many consumer healthcare products. Its portfolio extends beyond the URGO brand itself.

URGO Medical

The professional healthcare division specializing in advanced wound care, particularly complex and chronic wounds treated by healthcare professionals.

URGO Group

The parent family-owned healthcare group encompassing these activities and numerous other brands. The Group’s portfolio includes brands such as Juvamine, Mercurochrome, Alvityl, Humer, Super Diet, Marie Rose, Ricqlès, Urgo K2, and others. 7

The modern URGO Group is considerably larger than the URGO brand itself. It operates across three broad areas:

1. Consumer healthcare
2. Medical / professional wound care
3. Research, industrial development, and healthcare innovation

The company describes itself as a family-owned French group, with the Le Lous family involved for three generations. Current governance includes Tristan, Briac, and Guirec Le Lous. Tristan Le Lous serves as chairman of the Group, while the family’s businesses have specialized leadership across its healthcare divisions.

The Group reported:

• €930 million revenue in 2025
• 4,000 employees
• Presence in 20 countries
• 60% of revenue generated internationally

In May 2026, URGO announced that it had surpassed €1 billion in turnover, marking another significant milestone in the Group’s expansion. 8

Although URGO originated in France, international expansion became an increasingly important part of its strategy. The Group established a presence in Germany during the 1980s and entered Asian markets during the following decade. During the 2000s, it expanded throughout Europe, including the United Kingdom, Spain, Italy, Poland, and Belgium, followed by expansion into Latin America, Australia, and the United States. 9

The American business was strengthened in 2018 through the acquisition of SteadMed, a company specializing in advanced wound-care products.

Today, URGO’s products and the wider Group’s healthcare solutions reach markets well beyond France.

URGO’s brand positioning can broadly be described as:

Accessible healthcare combined with scientific and technological innovation.

This combination places URGO between two worlds:

Mass-market consumer healthcare
→ Pharmacies, families, first aid, everyday skin problems

and

Professional medical care
→ Hospitals, clinicians, chronic wounds, and advanced wound-healing technologies

The brand’s heritage provides strong recognition in the first category, while URGO Medical supplies technological and clinical expertise in the second.

URGO retains a strong French identity. Created in Dijon in 1958, the Group continues to emphasize French R&D, industrial expertise, and manufacturing. URGO describes itself as a French healthcare company whose industrial capabilities are an important part of its competitive advantage.

This gives URGO a positioning similar to other long-established French pharmacy brands: French origin + pharmacy distribution + scientific credibility + everyday consumer familiarity. However, the company operates internationally, meaning that “French brand” should not be confused with “products exclusively manufactured in France.”

Innovation is central to URGO’s corporate identity. The Group follows a model of “double innovation”: when developing a healthcare product, its teams may simultaneously develop the industrial technology required to manufacture it at scale. Researchers, clinicians, and production engineers work together during product development.

This approach is relevant because advanced dressings are not simply pharmaceutical formulations. Their performance depends on:

• Materials science
• Adhesive technology
• Polymers
• Wound environment
• Moisture management
• Mechanical properties
• Skin compatibility
• Manufacturing processes
• Clinical evidence

Consequently, URGO’s competitive identity is based not only on marketing a familiar pharmacy brand but also on materials and medical-device innovation.

URGO is unusual among major healthcare companies because the wider Group remains family-owned. The Le Lous family has been involved in the business for three generations. The Group emphasizes its independence and long-term investment approach, rather than operating as a publicly listed pharmaceutical corporation.

In 2019, URGO introduced a rotating family-chairmanship system involving Hervé Le Lous’ three sons. Briac Le Lous served as chairman until 2022, after which Tristan Le Lous became chairman.

The wider URGO organization created the Fondation URGO in 2010. Its purpose is to support healthcare professionals through education and training and to contribute to initiatives intended to improve wound-care practices and patient care. This aligns with URGO’s positioning around wound healing, as the company participates in professional education and healthcare initiatives alongside its consumer-products business.

From a brand perspective, URGO’s development can be summarized in four stages:

1958 — The Plaster
URGO begins as a brand making ready-to-use dressings accessible to consumers.

↓

2000s — The Technology
It develops advanced wound-care technologies such as lipido-colloid dressings and Filmogel®.

↓

2010s — The Healthcare Ecosystem
The wider Group expands internationally and develops professional medical, consumer-health, and specialized healthcare businesses.

↓

2020s — The Broader Health Brand
URGO increasingly addresses not only wounds but also skin, feet, nails, mouth, acne, and other everyday health concerns.

This evolution explains why the modern URGO brand looks very different from the company founded in 1958: its historical DNA is still wound care, but its commercial identity has expanded toward everyday health and skin care.

1. La marque – Urgo
2. URGO, un groupe familial engagé
3. Notre histoire – Urgo Medical
4. URGO – Pansements, traitements et soins ampoules, aphtes, verrues, crevasses, ongles abîmés…
5. Filmogel® technology | Drupal POC URGO
6. URGO, a group committed to its healthcare mission
7. Qui sommes-nous ? – URGO
8. About Us | URGO
9. Home | Drupal POC URGO